Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCHIX:CEVIS 97 Cash-to-Debt is 3.29 as of Jun. 2026, which is 13% above its 10-year median of 2.91. GuruFocus rates CHIX:CEVIS with a GF Score™ of 97/100 and a GF Value™ of kr187.28. The stock has 2 warning signs investors should review. Among 840 Medical Devices & Instruments companies, CellaVision AB ranks better than 60.83% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CellaVision AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.29.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CellaVision ABcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for CellaVision AB's Cash-to-Debt or its related term are showing as below:
CHIX:CEVIs'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4 Med: 2.91 Max: No Debt
Current: 3.29
During the past 13 years, CellaVision AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.40. And the median was 2.91.
CHIX:CEVIs's Cash-to-Debt is ranked better than 60.83% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs CHIX:CEVIs: 3.29
CellaVision AB (CHIX:CEVIs) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
CellaVision AB Cash-to-Debt Related Terms
CellaVision AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:CEVIS vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, CellaVision AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where CellaVision AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CHIX:CEVIS) has a Cash-to-Debt of 3.29 as of Jun. 2026. This is 13% above median its historical median of 2.91. Over the past decade, CellaVision AB's Cash-to-Debt has ranged from 0.40 to 10,000.00. According to the industry distribution chart, CellaVision AB ranks #329 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 39.2%.
Is CellaVision AB's Cash-to-Debt too high?
CellaVision AB's current Cash-to-Debt of 3.29 is 13% above median its 10-year median of 2.91. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. CellaVision AB's value of 3.29 is 101.2% above this industry median. Based on the distribution chart, CellaVision AB ranks #329 out of 840 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #329 out of 840 companies for Cash-to-Debt. This puts CellaVision AB in the upper half of its industry. The industry median Cash-to-Debt is 1.64. CellaVision AB's value of 3.29 is 101.2% above this benchmark. Historically, CellaVision AB's own Cash-to-Debt has ranged from 0.40 to 10,000.00 over the past decade. While the company's 10-year median is 2.91 vs. the industry median of 1.64, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current Cash-to-Debt of 3.29 is 101.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current Cash-to-Debt is 3.29, which is 13% above median its own 10-year median of 2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Cash-to-Debt of 3.29. The stock's GF Value™ is kr187.28, compared to a current price of kr160.20 — trading 14.5% below its estimated fair value. The current Cash-to-Debt is 3.29, which is 13% above median its 10-year median of 2.91 and 101.2% above the Medical Devices & Instruments industry median of 1.64. CellaVision AB's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Cash-to-Debt is 3.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 14.5% below its estimated GF Value™ of kr187.28.
Key valuation signals for CHIX:CEVIS:
Cash-to-Debt: 3.29 (13% above median its 10-year median of 2.91)
GF Value™: kr187.28 vs. price of kr160.20 (14.5% below fair value)
Industry Position: 101.2% above the Medical Devices & Instruments median (#329 of 840)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
97GF Score
Get the complete analysis for CHIX:CEVIS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
